Keyword: Competition and Markets Authority
With U.S. and U.K. regulators continuing to review its $4.3 billion buyout of Spark, Roche is pushing back the deadline for the deal to April 2020.
After U.K. antitrust authorities smacked Pfizer with a record fine over a 2,600% price hike, the drugmaker won an appeal.
U.K. antitrust watchdogs are targeting Concordia and its pricing for liothyonine, a thyroid drug that now costs 57 times more than it did in 2006.
The U.K.’s competition authority claims Merck's Remicade discounts, aimed at defending against biosimilar competition, “broke competition law."
Officials in the U.K. are taking issue with huge price hikes, now targeting Actavis for a 12,000% increase.
The U.K. government slapped Pfizer with a record price-gouging fine for triggering a 2,600% price increase on an epilepsy drug.